VEGFA and hepatocellular carcinoma: On the basis of the above discussions, the primary objectives of the retrospective cohort study that we conducted were to (i) reassess the survival difference between combination therapy and TACE alone according to our data, (ii) explore the prognostic and predictive value of VEGF and other clinical characteristics in HCC patients treated with TACE, and (iii) estimate the association between baseline VEGF concentrations and the risk of death in patients with unresectable HCC.